Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: Comparative evaluation of prediction approaches in early drug development

Biopharmaceutics and Drug Disposition

Volumn 37, Issue 2, 2016, Pages 51-65

  Wang, Jing ^a,b   Iyer, Suhasini ^c,d   Fielder, Paul J ^c   Davis, John D ^c,e   Deng, Rong ^c  

^a Takeda San Diego Inc   (United States)

^b TESARO   (United States)

^c GENENTECH INC   (United States)

^d ABBVIE INC   (United States)

^e REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

allometry scaling; monoclonal antibody; pharmacokinetics; species invariant time method; target mediated drug disposition

Indexed keywords

MONOCLONAL ANTIBODY;

ALLOMETRY; DECISION TREE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; HUMAN; IMMUNOGENICITY; NONHUMAN; PREDICTION; REVIEW; ANIMAL; BIOLOGICAL MODEL; COMPARATIVE STUDY; PRECLINICAL STUDY;

ANIMALS; ANTIBODIES, MONOCLONAL; DECISION TREES; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, BIOLOGICAL;

EID: 84962343549     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1952     Document Type: Review

References (81)

1. Reichert JM,. Marketed therapeutic antibodies compendium. MAbs 2012; 4 (3): 413-415.
2. Deng R, Jin F, Prabhu S, Iver S,. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol 2012; 8 (2): 141-160.
3. Dedrick RL,. Animal scale-up. J Pharmacokinet Biopharm 1973; 1 (5): 435-461.
4. Mahmood I,. Pharmacokinetic allometric scaling of antibodies: application to the first-in-human dose estimation. J Pharm Sci 2009; 98 (10): 3850-3861.
5. Oitate M, Nakayama S, Ito T, Kurihara A, Okudaira N, Izumi T,. Prediction of human plasma concentration-time profiles of monoclonal antibodies from monkey data by species-invariant time method. Drug Metab Pharmacokinet 2012; 27 (3): 354-359.
6. Jolling K, Perez Ruixo JJ, Hemeryck A, Vermuelen A, Greway T,. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci 2005; 24 (5): 465-475.
7. Shah DK, Betts AM,. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 2012; 39 (1): 67-86.
8. Ling J, Zhou H, Jiao Q, Davis HM,. Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 2009; 49 (12): 1382-1402.
9. Wang W, Prueksaritanont T,. Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos 2010; 31 (4): 253-263.
10. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S,. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 2011; 3 (1): 61-66.
11. Dong JQ, Salinger DH, Endres CJ, et al., Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 2011; 50 (2): 131-142.
12. Oitate M, Masubuchi N, Ito T, et al., Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data. Drug Metab Pharmacokinet 2011; 26 (4): 423-430.
13. Betts AM, Clark TH, Yang J, et al., The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 2010; 333 (1): 2-13.
14. Luu KT, Bergquist S, Chen E, Hu-Lowe D, Kraynove E,. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition. J Pharmacol Exp Ther 2012; 341 (3): 702-708.
15. Kohler G, Milstein C,. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256 (5517): 495-497.
16. Harding FA, Stickler MM, Razo J, DuBridge RB,. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010; 2 (3): 256-265.
17. Lobo ED, Hansen RJ, Balthasar JP,. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93 (11): 2645-2668.
18. Zhao L, Shang EY, Sahajwalla CG,. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development. J Pharm Sci 2012; 101 (12): 4367-4382.
19. Dirks NL, Meibohm B,. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49 (10): 633-659.
20. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH,. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49 (8): 493-507.
21. Junghans RP,. Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res 1997; 16 (1): 29-57.
22. Brambell F, Hemmings W, Morris I,. A theoretical model of gamma-globulin catabolism. Nature 1964; 203: 1352-1355.
23. Roopenian DC, Akilesh S,. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7 (9): 715-725.
24. Berinstein NL, Grillo-Lopez AJ, White CA, et al., Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9 (9): 995-1001.
25. West GB, Brown JH,. The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization. J Exp Biol 2005; 208 (9): 1575-1592.
26. Boxenbaum H,. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 1984; 15 (5-6): 1071-1121.
27. Boxenbaum H, Ronfeld R,. Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 1983; 245 (6): R768-R775.
28. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD,. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 1991; 8 (11): 1351-1359.
29. Mahmood I,. Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci 2004; 93 (1): 177-185.
30. Lin YS, Nguyen C, Menoza JL, et al., Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 1999; 288 (1): 371-378.
31. Kelley SK, Gelzleichter T, Xie D, et al., Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 2006; 148 (8): 1116-1123.
32. Vugmeyster Y, Szklut P, Tchistiakova L, Abraham W, Kasaian M, Xu X,. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms. Int Immunopharmacol 2008; 8 (3): 477-483.
33. Ober RJ, Radu CG, Ghetie V, Ward ES,. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001; 13 (12): 1551-1559.
34. Petkova SB, Akilesh S, Sproule TJ, et al., Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 2006; 18 (12): 1759-1769.
35. Deng R, Mortensen D, Prabhu S, Jumbe N, Iyer S, Fielder PJ,. Prediction of human pharmacokinetics for monoclonal antibody. AAPS National Biotechnology Conference, San Diego, CA, 2007. http://www.aapsj.org/abstracts/NBC-2007/NBC07-000591.PDF.
36. Dall'Acqua WF, Kiener PA, Wu H,. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281 (33): 23514-23524.
37. Dall'Acqua WF, Woods RM, Ward ES, et al., Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 2002; 169 (9): 5171-5180.
38. Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I,. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem 2010; 285 (7): 4826-4836.
39. Yeung YA, Leabman MK, Marvin JS, et al., Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009; 182 (12): 7663-7671.
40. Proetzel G, Roopenian DC,. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Methods 2014; 65 (1): 148-153.
41. Tam SH, McCarthy SG, Brosnan K, Goldberg KM, Scallon BJ,. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities MAbs 2013; 5 (3): 397-405.
42. Mahmood I, Balian JD,. Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. J Pharm Sci 1996; 85 (4): 411-414.
43. Davies B, Morris T,. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10 (7): 1093-1095.
44. Tang H, Mayersohn M,. A mathematical description of the functionality of correction factors used in allometry for predicting human drug clearance. Drug Metab Dispos 2005; 33 (9): 1294-1296.
45. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN,. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. Cancer Res 1986; 46 (8): 3969-3978.
46. Baxter LT, Zhu H, Mackensen DG, Jain RK,. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 1994; 54 (6): 1517-1528.
47. Baxter LT, Zhu H, Mackensne DG, Butler WF, Jain RK,. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 1995; 55 (20): 4611-4622.
48. Davda JP, Jain M, Batra SK, Gwilt PR, Robinson DH,. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol 2008; 8 (3): 401-413.
49. Ferl GZ, Wu AM, DiStefano JJ 3rd.,. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng 2005; 33 (11): 1640-1652.
50. Garg A, Balthasar JP,. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 2007; 34 (5): 687-709.
51. Deng R, Loyet KM, Lien S, et al., Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 2010; 38 (4): 600-605.
52. Chen Y, Balthasar JP,. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. AAPS J 2012; 14 (4): 850-859.
53. Gurbaxani B, De la Cruz LL, Chintalacharuvuv K, Morrison SL,. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol 2006; 43 (9): 1462-1473.
54. Gurbaxani B, Dostalek M, Gardner I,. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? Mol Immunol 2013; 56 (4): 660-674.
55. Datta-Mannan A, Witcher DR, Lu J, Wroblewski VJ,. Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys. MAbs 2012; 4 (2): 267-273.
56. Zhao P, Rowland M, Huang SM,. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther 2012; 92 (1): 17-20.
57. Levy G,. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 1994; 56 (3): 248-252.
58. Till AE, Gomez HJ, Hichens M, et al., Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers. Biopharm Drug Dispos 1984; 5 (3): 273-280.
59. Mager DE, Mascelli MA, Kleiman NS, Fitzgerald DJ, Abernethy DR,. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther 2003; 307 (3): 969-976.
60. Meijer RT, Koopmans RP, ten Berge IJ, Schellekens PT,. Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen. J Pharmacol Exp Ther 2002; 300 (1): 346-353.
61. Marathe A, Peterson MC, Mager DE,. Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther 2008; 326 (2): 555-562.
62. Lammerts van Bueren JJ, Bleeker WK, Bogh HO, et al., Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 2006; 66 (15): 7630-7638.
63. Golay J, Semenzato G, Rambaldi A, et al., Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs 2013; 5 (6): 826-837.
64. Mager DE, Jusko WJ,. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28 (6): 507-532.
65. Yan X, Mager DE, Krzyzanski W,. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 2010; 37 (1): 25-47.
66. Mager DE, Krzyzanski W,. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 2005; 22 (10): 1589-1596.
67. Gibiansky L, Gibiansky E,. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol 2009; 5 (7): 803-812.
68. Gibiansky L, Gibiansky E, Kakkar T, Ma P,. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 2008; 35 (5): 573-591.
69. Mager DE, Woo S, Jusko WJ,. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 2009; 24 (1): 16-24.
70. Duconge J, Castillo R, Crombet T, et al., Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody. Eur J Pharm Sci 2004; 21 (2-3): 261-270.
71. Kagan L, Abraham AK, Harrold JM, Mager DE,. Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res 2010; 27 (5): 920-932.
72. Deng R, Meng YG, Hoyte K, et al., Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. MAbs 2012; 4 (1): 101-109.
73. Wang W, Wang EQ, Balthasar JP,. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84 (5): 548-558.
74. Kagan L, Turner MR, Balu-Iyer SV, Mager DE,. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res 2012; 29 (2): 490-499.
75. Zheng Y, Tesar DB, Benincosa L, et al., Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. MAbs 2012; 4 (2): 243-255.
76. Ng CM, Loyet KM, Iyer S, Fielder PJ, Deng R,. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-alpha IgG antibody in cynomolgus monkey. Eur J Pharm Sci 2014; 51: 51-58.
77. Chiba K, Yoshitsuga H, Kyosaka Y, et al., A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: Are Japanese phase I studies still needed? J Clin Pharmacol 2014; 54 (5): 483-494.
78. Chetty M, Li L, Rose R, et al., Prediction of the pharmacokinetics, pharmacodynamics, and efficacy of a monoclonal antibody, using a physiologically based pharmacokinetic FcRn model. Front Immunol 2014; 5: 670.
79. Bumbaca D, Wong A, Drake E, et al., Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs 2011; 3 (4): 376-386.
80. Vugmeyster Y, Szklut P, Wensel D, et al., Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti-abeta Ab2, in nonclinical species. Pharm Res 2011; 28 (7): 1696-1706.
81. Xin Y, Bai S, Damico-Beyer LA, et al., Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans. Pharm Res 2012; 29 (9): 2512-2521.